The therapeutic effect of a combination of cofpropamine, a caffeine derivative, and cyclophosphamide on the development of adjuvant arthritis of rats and collagen arthritis of mice.
1. Cofpropamine (Cofa), a caffeine derivative that inhibits polyadenoribosylation, enhances the therapeutic effect of cyclophosphamide (CPA) in two animal models of arthritis. 2. The development of adjuvant arthritis of rats is reduced by treatment with 2 x 50 mg/kg IP CPA and 2 x 50 mg/kg IP Cofa. 3. The development of collagen arthritis in mice is prevented by treatment with 12.5 mg/kg IP CPA and 150 mg/kg IP Cofa three times per week.
Kröger
H
H
Deutsches Rheumaforschungszentrum Berlin, Germany.
Klosa
J
J
Grätz
R
R
Dietrich
A
A
Ehrlich
W
W
Wild
A
A
D000477:Alkylating Agents / Q000627:therapeutic use*; D000818:Animals; D001169:Arthritis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D001835:Body Weight / Q000187:drug effects; D002110:Caffeine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003094:Collagen; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005528:Foot / Q000473:pathology; D007596:Joints / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D051381:Rats; D017208:Rats, Wistar
D000477:Alkylating Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C104858:cofpropamine; D002110:Caffeine; D003520:Cyclophosphamide; D003094:Collagen